Accelerating cancer research through comprehensive genomic analysis
)
Overview
Cancer is a challenging multifactorial disease and the rapid advancement of sequencing technologies over the last two decades has revealed unprecedented insights into the genomic causes and implications of cancer. However, a vast proportion of cancers cannot be explained by simple point mutations detected using legacy short-read sequencing technologies.
In this white paper, discover how Oxford Nanopore sequencing technology provides extensive analyses of structural variants, repeat regions, DNA/RNA methylation, cell-free and circulating tumour DNA (cfDNA and ctDNA), fusion genes and full-length transcript isoforms to truly understand cancer biology.
In this white paper, you will:
- Learn the importance of cancer research and its recent developments
- Discover the limitations of legacy sequencing technologies
- Find out how Oxford Nanopore sequencing overcomes these limitations
- Read real-world case studies of how researchers are utilising Oxford Nanopore sequencing to deliver new insights into a wide range of cancers, including retinoblastoma, acute pediatric leukaemia, and hereditary cancer
